CompletedNot Applicable

Utilisation of Angiox® in European Practice

France, Germany2,019 participantsStarted 2009-05

Plain-language summary

The objective of this study is to determine utilisation patterns in patients receiving Angiox® in participating European centres. Additionally, through the collection of descriptive safety and outcomes data, this study will contribute to the Risk Management strategy for Europe

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Eligible for, and receive treatment with Angiox®. * Willing and able to provide written informed consent to the use of their data in accordance with relevant local Data Protection laws, policies and regulations Exclusion Criteria: * Participation in other interventional clinical research studies involving the evaluation of investigational drugs, including Angiox®, or devices at the time of enrolment. * Patients not eligible for treatment for Angiox®.

What they're measuring

Posology and usage patterns of Angiox®: Dose(s) and time of bolus and infusion administered

Timeframe: from hospital admission until hospital discharge, or 7 days after administration (which ever is earlier).

Trial details

NCT IDNCT01011504

SponsorThe Medicines Company

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2010-10

View on ClinicalTrials.gov More Stable Angina (SA) trials